Arcutis BiotherapeuticsARQT
Recorded

Arcutis Biotherapeutics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 15 minParticipants14

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please be advised that today's conference is being recorded. I would like now to turn the conference over to Brian Schoelkopf, Head of Investor Relations. Please go ahead. Thank you, Michelle.

Brian SchoelkopfHead of Investor Relations

Good afternoon, everyone, and thank you for joining us today to review our third quarter 2026 financial results and business update. Slides for today's call are available on the investors section of the Arcutis website. Joining me on the call today are Frank Watanabe, President and CEO of Arcutis, Rob Lisicki, Chief Commercial Officer, Patrick Burnett, Chief Medical Officer, and Latha Vairavan, Chief Financial Officer. I would like to remind everyone that we will be making forward-looking statements during this call. These statements are subject to certain risks and uncertainties, and our actual results may differ. We encourage you to review all of the company's filings with the Securities and Exchange Commission, including descriptions of our business and risk factors. With that, I will now turn the call over to Frank to begin today's call.

Frank WatanabePresident and CEO

Thanks, Brian, and good afternoon, everybody. As always, we appreciate you joining us for our quarterly update call. It is hard to believe that we are now in the fourth and final quarter of 2026. As I start this afternoon, I am going to start with a review of the business and our progress that we have made in our third quarter as we continue to execute against our grow, expand, and build corporate strategy, and to deliver on our mission to bring meaningful innovation to individuals living with chronic inflammatory skin diseases. I will then take a couple of minutes to address a question that we have been getting a lot recently, namely our approach to the application of artificial intelligence at Arcutis.

Frank WatanabePresident and CEO

I will then turn it over to Rob for a commercial update, then Patrick will provide an update on our R&D programs and initiatives, and we will finish with a review of the quarter's financial results from Latha before we open it up to your questions. On slide five, it has been a year since we unveiled our three-pillar grow, expand, and build strategy to sustain near and long-term corporate growth. In the third quarter, once again, we made notable progress across all three pillars. I will start with the grow pillar, comprising activities that are designed to strengthen our core ZORYVE business across our three current indications, plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. In late September, we announced an incredibly exciting new partnership with world champion gymnast Simone Biles to launch our Skin to Believe In awareness campaign.

Frank WatanabePresident and CEO

The goal of this ambitious multi-channel campaign is to encourage the nearly 36 million Americans living with either eczema or seborrheic dermatitis to talk to their doctor about long-term, steroid-free topical treatment options for their chronic skin diseases. Through the campaign, Simone will share her own experience of living with and managing her seborrheic dermatitis and eczema, including her experience using ZORYVE foam and cream. It's truly an honor for us to be partnering with Simone, one of the most recognized and well-respected athletes in the world. Simone is an authentic and trusted advocate of health and wellness issues, making her an extraordinarily powerful brand ambassador. By sharing her story about her challenges of living with these skin conditions, Simone will undoubtedly help empower others to take control of their skin health by speaking with their healthcare provider about advanced topical treatments like ZORYVE.

Frank WatanabePresident and CEO

This awareness campaign is meaningful in its own right and is also synergistic with our other commercial initiatives, such as virtual health and our primary care and pediatric sales force that we've been rolling out throughout the year. Collectively, these initiatives are designed to generate awareness of ZORYVE's differentiated therapeutic profile among both clinicians and patients, and then enable efficient patient access to ZORYVE when it's identified as the appropriate therapeutic intervention. Across these initiatives, we're reinvesting the cash flow we're generating from ZORYVE back into the franchise to drive sustained growth and inflection in sales in 2027. Also under the grow pillar, we're really excited to announce the initiation of a new trial that will evaluate ZORYVE cream 0.3% for the treatment of moderate to severe atopic dermatitis.

Frank WatanabePresident and CEO

ZORYVE cream 0.15% is already embedded as an important treatment option for clinicians for the treatment of mild to moderate atopic dermatitis, and the intent of this trial, as Patrick will detail shortly, is to evaluate ZORYVE in these more severe patients who need similarly effective and well-tolerated treatment options for the management of their chronic inflammatory skin disease as less severe patients. We're also eagerly awaiting the February 2027 PDUFA date for ZORYVE cream 0.05% as a treatment for mild to moderate atopic dermatitis in infants aged three to 24 months, with launch preparations already underway. This expanded indication will be based on the strength of the data from our phase II INTEGUMENT-INFANT trial. We're excited by the potential to bring an effective, non-steroidal topical treatment safe to use anywhere on the body and for any duration of time to this infant patient population and their caregivers.

Frank WatanabePresident and CEO

There's very high clinician anticipation for this potential indication, as they currently really struggle with inadequate options for treating this most vulnerable patient group. These clinical investments that we're making in our inline ZORYVE business will further bolster the medium-term growth of the franchise, as will investments we are making to explore potential indication expansions. Now turning to the expand pillar and our ongoing efforts to potentially broaden the application of ZORYVE to individuals with unmet needs across a range of additional inflammatory skin conditions, as guided by the expansive body of compelling case reports with ZORYVE. As we've announced previously, we've now completed enrollment in our phase II proof of concept trial of vitiligo.

Frank WatanabePresident and CEO

We remain on track to provide a readout from the vitiligo trial in the fourth quarter of this year, as well as a decision on whether we will advance the program based on those data. We continue to enroll the hidradenitis suppurativa, or HS, phase II proof of concept trials, and we anticipate a similar readout for the HS program late in the first quarter of 2027. We are also very excited about a new trial that we are just beginning that will evaluate the use of ZORYVE to treat the debilitating skin rashes that affect up to half of all patients treated with life-saving checkpoint inhibitor therapies like Keytruda and Opdivo. Ironically, these skin rashes are an indication of treatment effect, but they also frequently lead patients to reduce or even discontinue their treatment.

Frank WatanabePresident and CEO

A treatment option with a favorable safety and efficacy profile for these common side effects would be very well received. We continue to evaluate other potential indications and expect to announce additional phase II POC studies in the coming quarters. The breadth and ambition of our clinical pursuits with ZORYVE continue to be unrivaled in the branded non-steroidal topical segment. They are enabled by ZORYVE's differentiated therapeutic profile and the distinct and pleiotropic mechanism of action. While we are advancing them against the backdrop of increasing awareness of the harmful side effects of extended or inappropriate use of corticosteroids and a growing movement to shift the standard of care to advanced non-steroidal topical treatment. Put simply, we believe we are at the right time, in the right place, with the right drug.

Frank WatanabePresident and CEO

Finally, turning to the build pillar and our efforts to deepen our innovative pipeline beyond ZORYVE, where we continue to make progress on the phase I-A/I-B trial of ARQ-234, our novel biologic targeting CD200R as a potential treatment for moderate to severe atopic dermatitis. Additionally, as we have highlighted in previous calls, we anticipate that external innovation will play a key role in our pipeline expansion efforts. To that end, we continue to actively evaluate a range of external assets. There is a great deal of emerging scientific and therapeutic innovation across the dermatology and adjacent I&I landscape, and potential opportunities for impact are far-reaching and very exciting. Finally, as Latha will describe, we had another strong quarter financially.

Frank WatanabePresident and CEO

This sustained level of performance across our core ZORYVE business and the cash flow it is generating is enabling us to continue to invest in innovation, securing the foundation for the long-term success of Arcutis. On our Q2 call, you will recall that we increased our full year 2026 net revenue guidance by $45 million at the midpoint to between $525 million and $540 million, taking into consideration our strategic portfolio of investments and the continued strength of our core business. With visibility into the remainder of the year and the strength of our Q3 results, today we are further increasing that guidance range to between $535 million and $545 million. Before detailing our results for the quarter, I would like to spend a moment answering a question that we have been increasingly receiving, and I am on slide six now, namely our approach to adopting AI at Arcutis.

Frank WatanabePresident and CEO

You know, I think it's clear to everyone that artificial intelligence is having and will continue to have a meaningful impact on biotech, as with nearly every other sector of business. But as I've remarked previously, when all you have is a hammer, everything looks like a nail. We believe there's a risk that many companies will over-invest in AI programs that yield little or no tangible benefit to their customers and shareholders. At Arcutis, we're taking a measured and intentional approach to leveraging the power of AI in our business. We see the potential, but remain very thoughtful about when we use it and also how we protect our data, an essential issue in a knowledge-intensive business like biotech. Our disciplined approach begins by evaluating when and where AI can be an accelerator to our business.

Frank WatanabePresident and CEO

One key question has to be whether AI offers distinct advantages over other traditional approaches. Where AI makes sense, we look to pursue those projects with the greatest impact on our highest priority business objectives. Every AI project needs to have measurable value with the potential for a high return on investment. Lastly, and critically, we scrutinize every potential AI project to ensure we can protect our proprietary data and information. Using this disciplined approach, we have already identified more than 30 discrete use cases for AI across our business, some of which have already been deployed, and many more that are in the production phase.

Frank WatanabePresident and CEO

For example, we've recently equipped our field sales team with an industry-leading AI-enabled set of tools that help them harness all of the information at our disposal to better analyze their business, prioritize which clinicians to call on, what clinical data might be most relevant for the clinicians they interact with, and how best to present ZORYVE materials. These efforts are already having a positive impact and becoming an important component of our reps' toolkit. Rob, Patrick, and I were out in the field last week with our team, and we were impressed at how our team is rapidly leveraging these new tools to enhance their effectiveness. We're also partnering with companies deploying AI-enabled prescription workflow platforms to streamline the post-prescription process for medical offices, as we've previously detailed, and that facilitates a more seamless and efficient process for patients to receive their ZORYVE prescriptions once written.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day